<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39397227</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2192-4449</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>CEN case reports</Title><ISOAbbreviation>CEN Case Rep</ISOAbbreviation></Journal><ArticleTitle>A case of de novo glomerulonephritis following COVID-19 in a patient with preexistent IgA vasculitis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13730-024-00940-9</ELocationID><Abstract><AbstractText>During the unprecedented COVID-19 outbreak, new-onset or relapsing glomerulonephritis, such as ANCA-associated glomerulonephritis and Immunoglobulin A (IgA) nephropathy, following COVID-19 has been reported. However, to date, the association of COVID-19 with preexistent IgA vasculitis (IgAV) remains unclear. Here, we present the case of a 20-something old Japanese woman with preexistent IgAV who newly developed glomerulonephritis following COVID-19. At the diagnosis of IgAV, she had cutaneous purpura, joint pains, and gastrointestinal symptoms, but no signs of kidney involvement. Three months ago, she was tested positive for COVID-19 and subsequently developed hematuria and proteinuria. She was then admitted to our hospital and renal biopsy showed glomerular mesangial expansion and hypercellularity and cellular and fibrocellular crescents, accompanied by diffuse IgA and C3 deposits. With the diagnosis of de novo IgAV nephritis, the patient was treated with intravenous methylprednisolone followed by oral prednisolone. She had favorable responses to this treatment and has achieved and maintained the remission of hematuria and proteinuria after initiation of glucocorticoid therapy. Our case highlights that immune response to SARS-CoV-2 infection could trigger the onset of glomerulonephritis in the IgAV patients who have no renal involvement.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Japanese Society of Nephrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Daigo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshino</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9833-4356</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan. jyoshino@med.shimane-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Integrated Kidney Research and Advance (IKRA), Faculty of Medicine, Shimane University, Izumo, Shimane, Japan. jyoshino@med.shimane-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanada</LastName><ForeName>Maki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohba</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oka</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itoga</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niino</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Functional Pathology, Faculty of Medicine, Shimane University, Izumo, Shimane, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanda</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Integrated Kidney Research and Advance (IKRA), Faculty of Medicine, Shimane University, Izumo, Shimane, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>CEN Case Rep</MedlineTA><NlmUniqueID>101636244</NlmUniqueID><ISSNLinking>2192-4449</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Glomerulonephritis</Keyword><Keyword MajorTopicYN="N">Glucocorticoid therapy</Keyword><Keyword MajorTopicYN="N">IgA vasculitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39397227</ArticleId><ArticleId IdType="doi">10.1007/s13730-024-00940-9</ArticleId><ArticleId IdType="pii">10.1007/s13730-024-00940-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davin JC. Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol. 2011;6(3):679–89. https://doi.org/10.2215/CJN.06710810 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.06710810</ArticleId><ArticleId IdType="pubmed">21393485</ArticleId></ArticleIdList></Reference><Reference><Citation>Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein): current state of knowledge. Curr Opin Rheumatol. 2013;25(2):171–8. https://doi.org/10.1097/BOR.0b013e32835d8e2a .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e32835d8e2a</ArticleId><ArticleId IdType="pubmed">23318735</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu H, Fujimoto S, Yoshikawa N, Kitamura H, Sugiyama H, Yokoyama H. Clinical manifestations of Henoch-Schonlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2016;20(4):552–60. https://doi.org/10.1007/s10157-015-1177-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-015-1177-0</ArticleId><ArticleId IdType="pubmed">26456327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocevar A, Tomsic M, Jurcic V, Perdan Pirkmajer K, Rotar Z. Predicting gastrointestinal and renal involvement in adult IgA vasculitis. Arthritis Res Ther. 2019;21(1):302. https://doi.org/10.1186/s13075-019-2089-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-2089-2</ArticleId><ArticleId IdType="pubmed">31878954</ArticleId><ArticleId IdType="pmc">6933935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R, Lau S, Tan V, Tey HL. Adult Henoch-Schonlein purpura: Clinical and histopathological predictors of systemic disease and profound renal disease. Indian J Dermatol Venereol Leprol. 2017;83(5):577–82. https://doi.org/10.4103/ijdvl.IJDVL_571_16 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijdvl.IJDVL_571_16</ArticleId><ArticleId IdType="pubmed">28485308</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy GR, Kemeny L, Bata-Csorgo Z. Neutrophil-to-lymphocyte ratio: a biomarker for predicting systemic involvement in adult IgA vasculitis patients. J Eur Acad Dermatol Venereol. 2017;31(6):1033–7. https://doi.org/10.1111/jdv.14176 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.14176</ArticleId><ArticleId IdType="pubmed">28222228</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillebout E, Sunderkotter C. IgA vasculitis. Semin Immunopathol. 2021;43(5):729–38. https://doi.org/10.1007/s00281-021-00874-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-021-00874-9</ArticleId><ArticleId IdType="pubmed">34170395</ArticleId></ArticleIdList></Reference><Reference><Citation>Messova A, Pivina L, Muzdubayeva Z, Sanbayev D, Urazalina Z, Adams A. COVID-19 and new onset IgA Vasculitis: a systematic review of case reports. J Emerg Nurs. 2022;48(4):348–65. https://doi.org/10.1016/j.jen.2022.05.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jen.2022.05.002</ArticleId><ArticleId IdType="pubmed">35691763</ArticleId><ArticleId IdType="pmc">9098918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugita K, Kaneko S, Hisada R, Harano M, Anno E, Hagiwara S, et al. Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review. CEN Case Rep. 2022;11(4):436–41. https://doi.org/10.1007/s13730-022-00695-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13730-022-00695-1</ArticleId><ArticleId IdType="pubmed">35275366</ArticleId><ArticleId IdType="pmc">8914443</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka F, Nakatani S, Tsuda A, Mori K, Emoto M. Successful alternative vaccination with BNT162b2 mRNA COVID-19 vaccine for new-onset IgA vasculitis after receiving mRNA-1273-case report. CEN Case Rep. 2022;11(4):511–2. https://doi.org/10.1007/s13730-022-00735-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13730-022-00735-w</ArticleId><ArticleId IdType="pubmed">36114985</ArticleId><ArticleId IdType="pmc">9483241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, et al. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;11(3):358–62. https://doi.org/10.1007/s13730-021-00677-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13730-021-00677-9</ArticleId><ArticleId IdType="pubmed">35075622</ArticleId><ArticleId IdType="pmc">8786447</ArticleId></ArticleIdList></Reference><Reference><Citation>Valero C, Baldivieso-Acha JP, Uriarte M, Vicente-Rabaneda EF, Castaneda S, Garcia-Vicuna R. Vasculitis flare after COVID-19: report of two cases in patients with preexistent controlled IgA vasculitis and review of the literature. Rheumatol Int. 2022;42(9):1643–52. https://doi.org/10.1007/s00296-022-05153-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05153-w</ArticleId><ArticleId IdType="pubmed">35691980</ArticleId><ArticleId IdType="pmc">9188920</ArticleId></ArticleIdList></Reference><Reference><Citation>Klomjit N, Zand L, Cornell LD, Alexander MP. COVID-19 and glomerular diseases. Kidney Int Rep. 2023;8(6):1137–50. https://doi.org/10.1016/j.ekir.2023.03.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2023.03.016</ArticleId><ArticleId IdType="pubmed">37274308</ArticleId><ArticleId IdType="pmc">10041821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota Y, Kuroki R, Iwata M, Taira H, Matsuo S, Kamijo M, et al. Association between COVID-19 vaccination and relapse of glomerulonephritis. Clin Exp Nephrol. 2023;27(3):236–42. https://doi.org/10.1007/s10157-022-02299-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-022-02299-6</ArticleId><ArticleId IdType="pubmed">36422760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li Z, Wu Z, Wang F, Xing Y, Liu Y, et al. Clinical and pathological findings of IgA nephropathy following SARS-CoV-2 infection. Clin Exp Med. 2024;24(1):43. https://doi.org/10.1007/s10238-023-01271-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-023-01271-2</ArticleId><ArticleId IdType="pubmed">38400937</ArticleId><ArticleId IdType="pmc">10894116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramdani Y, Galempoix JM, Augusto JF, Dekmeer E, Perard L, Ferreira N, et al. Immunoglobulin A vasculitis following COVID-19: a french multicenter case series. J Rheumatol. 2022;49(12):1390–4. https://doi.org/10.3899/jrheum.220503 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.220503</ArticleId><ArticleId IdType="pubmed">36243405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho I, Kim JK, Kim SG. IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report. BMC Nephrol. 2022;23(1):403. https://doi.org/10.1186/s12882-022-03028-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-022-03028-7</ArticleId><ArticleId IdType="pubmed">36522629</ArticleId><ArticleId IdType="pmc">9751513</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens KI, Frangou E, Shin JIL, Anders HJ, Bruchfeld A, Schonermarck U, et al. Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrol Dial Transplant. 2022;37(8):1400–10. https://doi.org/10.1093/ndt/gfac052 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfac052</ArticleId><ArticleId IdType="pubmed">35244174</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman M, Sinaii N, Lerma EV, Kurien AA, Jhaveri KD, Uppal NN, et al. COVID-19 vaccination and new onset glomerular disease: results from the irocgn2 international registry. Kidney. 2023. https://doi.org/10.34067/KID.0006832022 .</Citation><ArticleIdList><ArticleId IdType="doi">10.34067/KID.0006832022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja MM, Ardalan M, et al. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. Rev Med Virol. 2021;31(3): e2176. https://doi.org/10.1002/rmv.2176 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2176</ArticleId><ArticleId IdType="pubmed">33022818</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J. Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep. 2019;4(12):1717–24. https://doi.org/10.1016/j.ekir.2019.08.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2019.08.015</ArticleId><ArticleId IdType="pubmed">31844808</ArticleId><ArticleId IdType="pmc">6895670</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700–5. https://doi.org/10.1016/j.kint.2017.10.019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.10.019</ArticleId><ArticleId IdType="pubmed">29329643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YS, Yang CW, Tsai CC, Ang MD, Chou SF, Chiang WC, et al. Newly-diagnosed immunoglobulin A nephropathy with increased plasma galactose-deficient-IgA(1) antibody associated with mRNA COVID-19 vaccination: a case report. J Int Med Res. 2022;50(10):3000605221129674. https://doi.org/10.1177/03000605221129674 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605221129674</ArticleId><ArticleId IdType="pubmed">36262058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002;13(5):1271–8. https://doi.org/10.1097/01.asn.0000013883.99976.22 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.asn.0000013883.99976.22</ArticleId><ArticleId IdType="pubmed">11961015</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppo R, Mazzucco G, Cagnoli L, Lupo A, Schena FP. Long-term prognosis of Henoch-schonlein nephritis in adults and children. Nephrol Dial Transplant. 1997. https://doi.org/10.1093/ndt/12.11.2277 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/12.11.2277</ArticleId><ArticleId IdType="pubmed">9394311</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha S, Sumingan N, Tan J, Alhous H, McWilliam L, Ballardie F. Henoch Schonlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM. 2006;99(4):253–65. https://doi.org/10.1093/qjmed/hcl034 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcl034</ArticleId><ArticleId IdType="pubmed">16565522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>